In adults ≥65, a 13-valent pneumococcal polysaccharide conjugate vaccine reduced the incidence of infections associated with vaccine-type strains (efficacy of 45-70%) but did not prevent community-acquired pneumonia from any cause (efficacy 5.1%; 95% CI −5.1 to 14.2).